The burden of rhinitis in Australia

First published: 02/02/2015

Last updated: 22/02/2024

Study Planned

Administrative details

EU PAS number

EUPAS8507

Study ID

27684

DARWIN EU® study

No

Study countries

Australia

Study description

A set of three studies that aim to evaluate the burden of rhinitis on healthcare in Australia by assessing the real life treatment of rhinitis using prescribing and over the counter information, and the effect of introducing Dymista to the Australian market

Study status

Planned

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

First published: 06/10/2015

Last updated: 20/08/2026

Institution | **Educational Institution** | **Laboratory/Research/Testing facility** | **ENCePP partner**

Contact details

Study institution contact

David Price dprice@opri.sg

Study contact

dprice@opri.sg

Primary lead investigator

David Price

Primary lead investigator

Study timelines

Date when funding contract was signed
Planned: 30/01/2015

Study start date
Planned: 06/02/2015

Data analysis start date
Planned: 14/02/2015

Actual: 18/03/2015

Date of final study report
Planned: 31/05/2015

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

MEDA Australia

Study protocol

R01414_Study 1 Rhinitis treatment patterns_Protocol_2015_V10.For_EnCEPP_02Feb15.pdf (491.59 KB)

R01414_Study 1 Rhinitis treatment patterns_Protocol_2015_V11.pdf (585.11 KB)

Regulatory

Was the study required by a regulatory body?

Unknown

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Other

If ‘other’, further details on the scope of the study

Real life treatment of rhinitis

Main study objective:

To evaluate the burden of rhinitis on healthcare in Australia by assessing the real life treatment of rhinitis using prescribing and over the counter information, and the effect of introducing Dymista to the Australian market

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medical condition to be studied

Rhinitis allergic

Population studied

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

Estimated number of subjects

50.000

Study design details

Outcomes

1) To assess the number of therapies (single vs. multiple drugs) used to treat rhinitis in Australia2) To describe the combination of therapies used to treat rhinitis in Australia3) To investigate the influence of OTC medications on the count and combination of therapies used to treat rhinitis in Australia, 4) To

investigate the seasonality of rhinitis treatment patterns5) To estimate the cost of rhinitis treatment in Australia6) To investigate the relationship between rhinitis treatment patterns and co-morbid asthma treatment

---

Data analysis plan

• Count of therapies will be reported as means and standard deviation SD, and/or median and inter-quartile range (25th and 75th percentiles) along with minimum and maximum values. Moreover, count of therapies will be presented as single, multiple and total number of therapies. • Within the multiple therapy patients group, the combination of different drug will be reported as absolute numbers as well as proportions and percentages.• Prescribed and over-the-counter medications will be reported as absolute numbers as well as proportions and percentages. • Time series analysis will be used to explore seasonality of rhinitis treatment patterns over the study period• The cost of rhinitis treatment will be reported as mean and median purchase (in Austrian dollars) along with their inter-quartile range and minimum and maximum values of purchases.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other

NostraData Australia

Data sources (types)

Drug dispensing/prescription data

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No